Logo-ps

 

Follower of ICMJE

Powered by:
Pharm Sci. 2017;23(1): 77-81. doi: 10.15171/PS.2017.12

Short Communication

An In Vitro Aerosolization Efficiency Comparison of Generic and Branded Salbutamol Metered Dose Inhalers

Sara Rahimkhani 1, Saeed Ghanbarzadeh 2, Ali Nokhodchi 3,4, Hamed Hamishehkar 5 *

Cited by CrossRef: 5

1- Miller J, Aldabet A, Soltani S, Golgoun S, Haroun M, Alkhayer M, Abdelwahed W. Development of an Ethanol-Free Salbutamol Sulfate Metered-Dose Inhaler: Application of Molecular Dynamic Simulation-Based Prediction of Intermolecular Interaction. SSRN Journal. 2022; [Crossref]
2- Rezaei H, Khoubnasabjafari M, Jouyban-Gharamaleki V, Hamishehkar H, Afshar Mogaddam M, Rahimpour E, Mehvar R, Jouyban A. A new method for investigating bioequivalence of inhaled formulations: A pilot study on salbutamol. J pharm pharm sci. 2023;26 [Crossref]
3- Jiang C, Bai R, Somavarapu S. Inhalable TPGS/DPPC Micelles Coloaded with Curcumin and Icariin for Targeted Lung Cancer Therapy. ACS Omega. 2025;10(15):15400 [Crossref]
4- Mahmoud T, Fouad A, Belal A, Ismail A, Baali F, Alharthi M, Hassan A, Roh E, Tulbah A, El-Ela F. Evaluating the bioavailability and therapeutic efficacy of nintedanib-loaded novasomes as a therapy for non-small cell lung cancer. Journal of Pharmaceutical Sciences. 2025;114(11):103998 [Crossref]
5- Aldabet A, Miller J, Soltani S, Golgoun S, Haroun M, Alkhayer M, Abdelwahed W. Development of an ethanol-free salbutamol sulfate metered-dose inhaler: Application of molecular dynamic simulation-based prediction of intermolecular interaction. European Journal of Pharmaceutics and Biopharmaceutics. 2022;179:118 [Crossref]
6- Jiang C, Somavarapu S. Design and development of DSPE-PEG2000/DPPC disk-like micelles for targeted delivery of icariin phytochemical in pulmonary fibrosis. International Journal of Pharmaceutics. 2024;667:124837 [Crossref]
7- Ghazwani S, Alhazmi S, Ghazwani S, Shubaily H, Wafi A, Alenazi N, Qadri M, Alshammari A, Mawkili W, Moshi J, Khired Z, Salama S. Improving the bioavailability of nintedanib by formulating inhalable ufasomes as a targeted therapy for non-small cell lung cancer. International Journal of Pharmaceutics: X. 2026;11:100482 [Crossref]
8- Hashem F, Abd Allah F, Abdel-Rashid R, Hassan A. Glibenclamide nanosuspension inhaler: development,in vitroandin vivoassessment. Drug Development and Industrial Pharmacy. 2020;46(5):762 [Crossref]

   Indexing & Abstracting: